151 related articles for article (PubMed ID: 29876620)
21.
Ohri N; Bodner WR; Halmos B; Cheng H; Perez-Soler R; Keller SM; Kalnicki S; Garg M
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):372-380. PubMed ID: 28068244
[TBL] [Abstract][Full Text] [Related]
22. Dynamic contrast-enhanced perfusion area-detector CT assessed with various mathematical models: Its capability for therapeutic outcome prediction for non-small cell lung cancer patients with chemoradiotherapy as compared with that of FDG-PET/CT.
Ohno Y; Fujisawa Y; Koyama H; Kishida Y; Seki S; Sugihara N; Yoshikawa T
Eur J Radiol; 2017 Jan; 86():83-91. PubMed ID: 28027771
[TBL] [Abstract][Full Text] [Related]
23. Local and regional treatment response by
van Diessen JNA; La Fontaine M; van den Heuvel MM; van Werkhoven E; Walraven I; Vogel WV; Belderbos JSA; Sonke JJ
Radiother Oncol; 2020 Feb; 143():30-36. PubMed ID: 31767474
[TBL] [Abstract][Full Text] [Related]
24. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
[TBL] [Abstract][Full Text] [Related]
25. Metabolic patterns on [
Holzgreve A; Taugner J; Käsmann L; Müller P; Tufman A; Reinmuth N; Li M; Winkelmann M; Unterrainer LM; Nieto AE; Bartenstein P; Kunz WG; Ricke J; Belka C; Eze C; Unterrainer M; Manapov F
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2466-2476. PubMed ID: 36951991
[TBL] [Abstract][Full Text] [Related]
26. What
Turgeon GA; Iravani A; Akhurst T; Beaulieu A; Callahan JW; Bressel M; Cole AJ; Everitt SJ; Siva S; Hicks RJ; Ball DL; Mac Manus MP
J Nucl Med; 2019 Mar; 60(3):328-334. PubMed ID: 30030343
[TBL] [Abstract][Full Text] [Related]
27. Maximum standardized uptake value of primary tumor (SUVmax_PT) and horizontal range between two most distant PET-positive lymph nodes predict patient outcome in inoperable stage III NSCLC patients after chemoradiotherapy.
Roengvoraphoj O; Käsmann L; Eze C; Taugner J; Gjika A; Tufman A; Hadi I; Li M; Mille E; Gennen K; Belka C; Manapov F
Transl Lung Cancer Res; 2020 Jun; 9(3):541-548. PubMed ID: 32676318
[TBL] [Abstract][Full Text] [Related]
28. Significance of
Kim E; Wu HG; Keam B; Kim TM; Kim DW; Paeng JC; Kim HJ; Chang JH
Clin Lung Cancer; 2019 Jan; 20(1):e9-e23. PubMed ID: 30266585
[TBL] [Abstract][Full Text] [Related]
29. PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment.
Iravani A; Turgeon GA; Akhurst T; Callahan JW; Bressel M; Everitt SJ; Siva S; Hofman MS; Hicks RJ; Ball DL; Mac Manus MP
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1869-1877. PubMed ID: 31190177
[TBL] [Abstract][Full Text] [Related]
30. Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer.
Choi NC; Fischman AJ; Niemierko A; Ryu JS; Lynch T; Wain J; Wright C; Fidias P; Mathisen D
Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):1024-35. PubMed ID: 12419428
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of qualitative response assessment interpretation criteria at 18F-FDG PET-CT for predicting outcome in locally advanced cervical carcinoma treated with chemoradiotherapy.
Scarsbrook A; Vaidyanathan S; Chowdhury F; Swift S; Cooper R; Patel C
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):581-588. PubMed ID: 27738729
[TBL] [Abstract][Full Text] [Related]
32. Imaging of hypoxia with 18F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy.
Trinkaus ME; Blum R; Rischin D; Callahan J; Bressel M; Segard T; Roselt P; Eu P; Binns D; MacManus MP; Ball D; Hicks RJ
J Med Imaging Radiat Oncol; 2013 Aug; 57(4):475-81. PubMed ID: 23870348
[TBL] [Abstract][Full Text] [Related]
33. Chemical Exchange Saturation Transfer MRI: Capability for Predicting Therapeutic Effect of Chemoradiotherapy on Non-Small Cell Lung Cancer Patients.
Ohno Y; Yui M; Yamamoto K; Takenaka D; Koyama H; Nagata H; Ueda T; Ikeda H; Ozawa Y; Toyama H; Yoshikawa T
J Magn Reson Imaging; 2023 Jul; 58(1):174-186. PubMed ID: 36971493
[TBL] [Abstract][Full Text] [Related]
34. Early CT and FDG-metabolic tumour volume changes show a significant correlation with survival in stage I-III small cell lung cancer: a hypothesis generating study.
van Loon J; Offermann C; Ollers M; van Elmpt W; Vegt E; Rahmy A; Dingemans AM; Lambin P; De Ruysscher D
Radiother Oncol; 2011 May; 99(2):172-5. PubMed ID: 21571382
[TBL] [Abstract][Full Text] [Related]
35. Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition.
Unterrainer M; Taugner J; Käsmann L; Tufman A; Reinmuth N; Li M; Mittlmeier LM; Bartenstein P; Kunz WG; Ricke J; Belka C; Eze C; Manapov F
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1407-1416. PubMed ID: 34664091
[TBL] [Abstract][Full Text] [Related]
36. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Langen HJ; Bares R
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):463-71. PubMed ID: 17103167
[TBL] [Abstract][Full Text] [Related]
37.
Luan X; Huang Y; Gao S; Sun X; Wang S; Ma L; Teng X; Lu H; Yu J; Yuan S
Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2336-2342. PubMed ID: 27631310
[TBL] [Abstract][Full Text] [Related]
38. Dynamic contrast-enhanced CT to assess metabolic response in patients with advanced non-small cell lung cancer and stable disease after chemotherapy or chemoradiotherapy.
Hwang SH; Yoo MR; Park CH; Jeon TJ; Kim SJ; Kim TH
Eur Radiol; 2013 Jun; 23(6):1573-81. PubMed ID: 23300040
[TBL] [Abstract][Full Text] [Related]
39. FDG-PET parameters as predictors of pathologic response and nodal clearance in patients with stage III non-small cell lung cancer receiving neoadjuvant chemoradiation and surgery.
Arnett AL; Packard AT; Mara K; Mansfield AS; Wigle DA; Haddock MG; Park SS; Olivier KR; Garces YI; Merrell KW
Pract Radiat Oncol; 2017; 7(6):e531-e541. PubMed ID: 28733185
[TBL] [Abstract][Full Text] [Related]
40. An investigative expansion of a competing risk model for first failure site in locally advanced non-small cell lung cancer.
Lacoppidan T; Vogelius IR; Pøhl M; Strange M; Persson GF; Nygård L
Acta Oncol; 2019 Oct; 58(10):1386-1392. PubMed ID: 31271118
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
